Ensysce Biosciences, Inc. announced that the PF614-201 study, 'A Randomized, Double-Blind, Placebo-Controlled Crossover Study of PF614 on Analgesic Response in the Cold Pressor Test in Healthy male Subjects' has completed enrollment. The goal of this exploratory Phase 2 PF614-201 study is to confirm the approximate time of onset for PF614 analgesic effects prior to initiation of Phase 3 efficacy evaluations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.524 USD | -3.23% | -6.60% | -50.57% |
21/03 | Transcript : Ensysce Biosciences, Inc., Q4 2023 Earnings Call, Mar 21, 2024 | |
15/03 | Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-50.57% | 3.97M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- ENSC Stock
- News Ensysce Biosciences, Inc.
- Ensysce Biosciences, Inc. Announces Enrollment Completion for PF614-201 Clinical Study